Enter your keyword

A Novel Approach for the Treatment of Acute Myeloid Leukemia

Mateon Therapeutics is developing OXi4503 for the treatment of acute myeloid leukemia. OXi4503 has a unique dual mechanism of action which causes the release of leukemic stem cells from the bone marrow and enables their destruction.

OXi4503 - A Unique Approach to the Treatment of Acute Myeloid Leukemia

OXi4503 has a unique dual mechanism of action that 1) disrupts shape of tumor bone marrow endothelial cells (BMECs) by tubulin depolymerization.  This releases adherent tumor cells from BMECs and activates the cell cycle making the tumor cells vulnerable to chemotherapy, and 2) directly kills tumor cells via myeloperoxidase activation.

Learn More About Our Science

A Management Team Highly Experienced in Product Development and Committed to Success

Meet the Mateon Therapeutics management team—world-class leaders with extensive track records in drug development.

Meet Our Team